title: Effect of fat-emulsion phospholipids on serum lipoprotein profile during 1 mo of cyclic total parenteral nutrition.
abstract: Changes in serum lipoprotein determined by selective precipitation were investigated in 11 adult patients during 1 mo of parenteral nutrition. Patients were divided into two groups that received a similar nutrient regimen except for Intralipid (IL) phospholipid, which was higher in group A (10% IL, n = 5) than in group B (20% IL, n = 6), 139 +/- 15 vs 71 +/- 0.5 mg.kg-1.d-1 (P less than 0.01). Lipoprotein X (LPX) detected soon after IL infusions were started reached its highest concentrations in group A. LPX concentrations correlated with phospholipid intakes on days 7 and 15 but not on day 29. Significant increases in the cholesterol and phospholipid content of low-density-lipoprotein-very-low-density-lipoprotein fractions were observed only in group A. It is suggested that these changes were induced by the twofold-higher intake of phospholipids in group A. With regard to the possible involvement of LPX in lipid overloading of the reticuloendothelial system and hepatocytes, administration of 20% IL seems preferable to 10% IL.
authors.affiliation: Clinique Gastro-entérologique, CHU Saint-Lazare, Lariboisière, France.
authors.forename: B
authors.initials: B
authors.lastname: Messing
authors.forename: J
authors.initials: J
authors.lastname: Peynet
authors.forename: J
authors.initials: J
authors.lastname: Poupon
authors.forename: A
authors.initials: A
authors.lastname: Pfeiffer
authors.forename: F
authors.initials: F
authors.lastname: Thuillier
authors.forename: O
authors.initials: O
authors.lastname: Chazouillères
authors.forename: A
authors.initials: A
authors.lastname: Legrand
mesh_terms: D000328:Adult; D000368:Aged; D005217:Fat Emulsions, Intravenous / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008073:Lipoprotein-X / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010289:Parenteral Nutrition, Total; D010743:Phospholipids / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D011897:Random Allocation
chemical_list: D005217:Fat Emulsions, Intravenous; D008073:Lipoprotein-X; D008074:Lipoproteins; D010743:Phospholipids